Figure S4.
BAL-0028 stabilizes NLRP3 in DARTS assays but does not synergize with MCC950 for NLRP3 inhibition. Related to Fig. 4. (A–C) Western blots showing NLRP3 expression and degradation in DARTS assays performed with (A) full-length human NLRP3-Twin-Strep-tag, (B) human NLRP3 1-688-ΔLRR-Twin-Strep-tag, or (C) human-NLRP3-mCherry. Cells and cell lysates were treated with 10 μM BAL-0028 or MCC950 or DMSO control (A and B) or 0.1–10 μM BAL-0028, 10 μM MCC950, or DMSO control (C). Blots shown are representative of (A) N = 3, (B) N = 2, and (C) N = 4 independent experiments. (D) IL-1β release from PMA-differentiated THP-1 cells primed with LPS and treated with 0.4–250 nM BAL-0028 or MCC950 or both compounds together. Graph symbols show average values from independent experiments performed in triplicate (indicated by different symbols) ± SEM. N = 2. Source data are available for this figure: SourceData FS4.

BAL-0028 stabilizes NLRP3 in DARTS assays but does not synergize with MCC950 for NLRP3 inhibition . Related to Fig. 4. (A–C) Western blots showing NLRP3 expression and degradation in DARTS assays performed with (A) full-length human NLRP3-Twin-Strep-tag, (B) human NLRP3 1-688-ΔLRR-Twin-Strep-tag, or (C) human-NLRP3-mCherry. Cells and cell lysates were treated with 10 μM BAL-0028 or MCC950 or DMSO control (A and B) or 0.1–10 μM BAL-0028, 10 μM MCC950, or DMSO control (C). Blots shown are representative of (A) N = 3, (B) N = 2, and (C) N = 4 independent experiments. (D) IL-1β release from PMA-differentiated THP-1 cells primed with LPS and treated with 0.4–250 nM BAL-0028 or MCC950 or both compounds together. Graph symbols show average values from independent experiments performed in triplicate (indicated by different symbols) ± SEM. N = 2. Source data are available for this figure: SourceData FS4.

This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal